Format

Send to

Choose Destination
Neurol Sci. 2010 Oct;31(5):565-9. doi: 10.1007/s10072-010-0262-0. Epub 2010 May 13.

Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Author information

1
Department of Neurology, University Hospital and Palacký University Medical School, I. P. Pavlova 6, 77520, Olomouc, Czech Republic. nevrly.martin@post.cz

Abstract

Peripheral metabolism of L-DOPA via enzyme catechol-O-methyltransferase (COMT) is one of the possible sources of homocysteine (HCY). The aim of this study was to assess plasma HCY levels in L-DOPA-treated Parkinson's disease (PD) patients and its influence by adding the inhibitor COMT (entacapone). Patients were divided into two groups: (1) patients long term treated with L-DOPA but were naïve to entacapone, (2) L-DOPA naïve patients, in whom a combined treatment with L-DOPA and entacapone was started. The HCY levels were higher in Group 1 than in Group 2. No statistically significant changes of HCY concentrations were found in both patient groups after adding entacapone to their L-DOPA treatments. Results of this study confirm that patients treated with L-DOPA for a long term have increased plasma HCY concentrations. We believe combined L-DOPA and entacapone therapy could be a possible protective mechanism against hyperhomocysteinemia in early PD.

PMID:
20464572
DOI:
10.1007/s10072-010-0262-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center